Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $16.7 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 5.55% year-over-year to $16.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.1 billion (up 5.07% YoY) and the FY2025 annual result came in at $16.2 billion, changed 0.45% from the prior year.
• Liabilities and Shareholders Equity improved to $16.7 billion in Q1 2026 per DGX's latest filing, from $16.2 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $16.7 billion in Q1 2026, with the low at $12.8 billion in Q1 2023.
• Average Liabilities and Shareholders Equity over 5 years is $14.6 billion, with a median of $14.0 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity slipped 5.69% in 2022 and grew 19.38% in 2024.
• Quest Diagnostics' Liabilities and Shareholders Equity stood at $12.8 billion in 2022, then increased by 9.23% to $14.0 billion in 2023, then rose by 15.2% to $16.2 billion in 2024, then advanced by 0.45% to $16.2 billion in 2025, then increased by 2.76% to $16.7 billion in 2026.
• Business Quant data shows DGX's Liabilities and Shareholders Equity at $16.7 billion in Q1 2026, $16.2 billion in Q4 2025, and $16.2 billion in Q3 2025.